The ONE InstantCare for COVID-19 Rapid Screening
SpectroChip Inc.
Back to Innovators
The ONE InstantCare developed by
SpectroChip uses its own “Spectral
Chip” technology to achieve a
quantitative analysis of antibody/
antigen. It is an important technology
that can achieve trace amounts and
quantitative tests for COVID-19 rapid
tests. The test process only takes
15 minutes to complete, and the
data can be uploaded to the cloud
database.
For suspected COVID-19 patients,
home isolation or follow-up of
confirmed patients, rapid screening
can help clarify the cause of the
patient, reduce the time of the
staying in hospitals, and serve
as a reference for whether it is
suitable for discharge. In the future,
relevant medical research and field
applications can be carried out on
a larger scale, which will help to a
certain extent on issues such as
epidemic control and community
prevention.
Highlights
- Rapid & Easy Test: It takes only about 15 minutes from sampling to get rapid quantitative results, and send the data to the cloud, with the easy operation of the mobile App.
- Accurate & High Sensitivity: Ability to accurately quantify antibodies (lgG/IgM) result, with a sensitivity of more than 200 times that of the existing rapid screening test, which can eliminate most false negatives and misjudgments.
- Cost Saving: Save time and cost by using rapid test strips and save medical resources for self-inspection.
- Wide Range of Application: COVID-19 antigen, IgM/IgG antibody, neutralising antibody can all be detected, and in the future, various detectors can also be developed in a wide range of applications such as telemedicine, home medical care, food safety, and industrial safety.
The ONE InstantCare: COVID-19 Immunoassay Total Solutions
